|
New Delhi, Jan 01: The subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) expert panel on Friday recommended approval of Oxford COVID-19 vaccine Covishield for emergency use in India, subject to certain regulatory provisions, official sources said.
The Pune-based Serum Institute of India (SII), the world”s largest vaccine manufacturer, has tied up with AstraZeneca to manufacture Covishield.
The SEC, which earlier had sought additional safety, immunogenicity and efficacy data from SII and Bharat Biotech, deliberated on their applications seeking emergency use authorisation (EUA) for their shots on Wednesday, and met again on Friday to review the matter.
While…
